v3.26.1
Consolidated Statements of Temporary Equity and Stockholders' Equity - USD ($)
$ in Thousands
Total
Conversion of Series B Preferred Stock to common stock
Exercise of warrants
Common Stock
Common Stock
Conversion of Series B Preferred Stock to common stock
Common Stock
Exercise of warrants
Additional Paid-in Capital
Additional Paid-in Capital
Conversion of Series B Preferred Stock to common stock
Additional Paid-in Capital
Exercise of warrants
Accumulated Deficit
Temporary equity outstanding (in shares) at May. 31, 2024 [1] 0                  
Temporary equity , beginning balance at May. 31, 2024 [1] $ 0                  
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Accretion of Series B Preferred Stock to redemption value (deemed dividend) $ 0                  
Temporary equity outstanding (in shares) at May. 31, 2025 [1] 0                  
Temporary equity , ending balance at May. 31, 2025 [1] $ 0                  
Beginning balance, common stock (in shares) at May. 31, 2024 [2]       138,217,000            
Balance, beginning period at May. 31, 2024 148,882     $ 138     $ 225,156     $ (76,412)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss $ (72,730)                 (72,730)
Ending balance, common stock (in shares) at May. 31, 2025 138,217,000     138,217,000 [2]            
Balance, ending period at May. 31, 2025 $ 76,152     $ 138     225,156     (149,142)
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Recapitalization adjustment resulting from reverse merger (in shares) [1] 6,000                  
Recapitalization adjustment resulting from reverse merger [1] $ 3,854                  
Conversion of Series B Preferred Stock to common stock (in shares) [1]   (3,000)                
Conversion of Series B Preferred Stock to common stock [1]   $ (1,955)                
Accretion of Series B Preferred Stock to redemption value (deemed dividend) [1] $ 113                  
Temporary equity outstanding (in shares) at May. 31, 2026 [1] 2,930                  
Temporary equity , ending balance at May. 31, 2026 [1] $ 2,012                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Capital contributions from Applied Parent 75,435           75,435      
Recapitalization adjustment resulting from reverse merger 53,769     $ 4     53,765      
Ekso Bionics Holdings, Inc. outstanding shares as of Business Combination date (in shares) [2]       3,565,000            
Proceeds from the issuance of common stock, net (in shares) [2]       1,311,000            
Proceeds from the issuance of common stock, net 15,000     $ 1     14,999      
Conversions of Series B Preferred Stock / Exercise of warrants (in shares) [2]         356,000 700,000        
Conversions of Series B Preferred Stock / Exercise of warrants   $ 1,955 $ 4,452     $ 1   $ 1,955 $ 4,451  
Accretion of Series B Preferred Stock to redemption value (deemed dividend) (113)           (113)      
Equity incentive (in shares) [2]       1,063,000            
Equity incentive 2,398     $ 1     2,397      
Stock-based compensation 1,297           1,297      
Net loss $ (50,320)                 (50,320)
Ending balance, common stock (in shares) at May. 31, 2026 145,212,000     145,212,000 [2]            
Balance, ending period at May. 31, 2026 $ 180,025     $ 145     379,342     (199,462)
Temporary equity , beginning balance at May. 05, 2026 3,854                  
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Accretion of Series B Preferred Stock to redemption value (deemed dividend) $ 113                  
Temporary equity outstanding (in shares) at May. 31, 2026 [1] 2,930                  
Temporary equity , ending balance at May. 31, 2026 [1] $ 2,012                  
Ending balance, common stock (in shares) at May. 31, 2026 145,212,000     145,212,000 [2]            
Balance, ending period at May. 31, 2026 $ 180,025     $ 145     $ 379,342     $ (199,462)
[1] Refer to Note 13. Temporary Equity for additional information regarding the January 2026 Series B Preferred Stock (as defined below).
[2] In accordance with Accounting Standards Codification (“ASC”) 805, the historical stockholders’ equity of the Company prior to the Business Combination (as defined below) has been retrospectively adjusted for the equivalent number of shares received in the share exchange with the difference between the par value of these shares and the consideration reflected in Additional Paid-in Capital. Refer to Note 3. Business Combinations for additional information.